Ginkgo Bioworks Holdings Inc [NYSE: DNA] gained 1.41% or -235.61 points to close at $1.30 with a heavy trading volume of 21.12M shares. The company report on February 1, 2024 at 7:00 AM that Bioluminescent Plants Are Now Even Brighter: Light Bio to Begin Selling Firefly Petunias to Consumers with USDA Approval.
Light Bio, an innovative synthetic biology startup, today announced that it is beginning to sell its groundbreaking bioluminescent petunias in the United States. With support from notable biotech leaders such as NFX and Ginkgo Bioworks (NYSE: DNA), Light Bio is reimagining the horticultural industry by introducing a new category of plants that emit an ethereal glow to enrich homes, gardens, and public spaces.
People are fascinated with glowing plants, and scientists have now revealed how to make these much brighter. This significant achievement, documented in Nature Methods, details genetic modifications which enhance bioluminescence in a variety of plants by up to 100 times. The team of 26 scientists, working across 9 research organizations, created the brighter plants by optimizing genes isolated from multiple species of luminous mushrooms.
The daily chart for DNA points out that the company has recorded -19.43% loss over the past six months.
If we look at the average trading volume of 1.30 shares, DNA reached to a volume of 21.12M in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Ginkgo Bioworks Holdings Inc [DNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DNA shares is $3.02 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DNA stock is a recommendation set at 3.14. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for Ginkgo Bioworks Holdings Inc shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on November 14, 2023.
The Average True Range (ATR) for Ginkgo Bioworks Holdings Inc is set at 0.10, with the Price to Sales ratio for DNA stock in the period of the last 12 months amounting to 8.95. The Price to Book ratio for the last quarter was 2.09, with the Price to Cash per share for the same quarter was set at 0.53.
Trading performance analysis for DNA stock
Ginkgo Bioworks Holdings Inc [DNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.02. With this latest performance, DNA shares dropped by 0.00% in over the last four-week period, additionally sinking by -19.43% over the last 6 months – not to mention a drop of -22.95% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DNA stock in for the last two-week period is set at 55.32, with the RSI for the last a single of trading hit 61.70, and the three-weeks RSI is set at 52.00 for Ginkgo Bioworks Holdings Inc [DNA]. The present Moving Average for the last 50 days of trading for this stock 1.4210, while it was recorded at 1.2920 for the last single week of trading, and 1.6544 for the last 200 days.
Ginkgo Bioworks Holdings Inc [DNA]: A deeper dive into fundamental analysis
Ginkgo Bioworks Holdings Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.78 and a Current Ratio set at 6.78.
Ginkgo Bioworks Holdings Inc [DNA]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Ginkgo Bioworks Holdings Inc posted -0.09/share EPS, while the average EPS was predicted by analysts to be reported at -0.21/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 57.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Ginkgo Bioworks Holdings Inc go to 31.70%.
An analysis of Institutional ownership at Ginkgo Bioworks Holdings Inc [DNA]
The top three institutional holders of DNA stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in DNA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in DNA stock with ownership which is approximately 5.8325%.